Precision BioSciences to Present Preclinical Data on Hepatitis B Treatment at EASL Congress
Precision BioSciences to Present Preclinical Data on Hepatitis B Treatment at EASL Congress
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies, today announced that the company will present preclinical data for its PBGENE-HBV clinical candidate at the European Association for the Study of the Liver Congress (EASL), highlighting the differentiated ability of ARCUS to make efficient, durable, and targeted elimination edits. The poster presentation highlights data in primary human hepatocytes demonstrating the high specificity and lack of detectable off-target editing for PBGENE-HBV at therapeutically relevant doses. The poster will also showcase non-human primate data demonstrating good tolerability of a multi-dosing approach for the treatment of chronic hepatitis B.
Precision BioSciences, Inc.（納斯達克股票代碼：DTIL）是一家利用其新型專有ARCUS平台開發活體基因編輯療法的先進基因編輯公司。該公司今天宣佈，該公司將在歐洲肝臟研究協會（EASL）上提供其PBGENE-HBV臨床候選藥物的臨床前數據，重點介紹ARCUS進行高效、持久和有針對性的消除編輯的差異化能力。海報展示重點介紹了原代人類肝細胞中的數據，這些數據表明 PBGENE-HBV 在治療相關劑量下具有很高的特異性且缺乏可檢測的脫靶編輯。海報還將展示非人類靈長類動物的數據，這些數據表明多劑量治療慢性乙型肝炎的方法具有良好的耐受性。